Holen Sie sich die Stockscreener-App
110.15
1.39%
-1.55
Handel nachbörslich:
110.15
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$111.70
Offen:
$110.59
24-Stunden-Volumen:
1.25M
Relative Volume:
0.88
Marktkapitalisierung:
$12.29B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$239.11M
KGV:
52.21
EPS:
2.1097
Netto-Cashflow:
$492.62M
1W Leistung:
-1.91%
1M Leistung:
+12.60%
6M Leistung:
-2.09%
1J Leistung:
+15.24%
1-Tages-Spanne:
$108.94
$111.76
1-Wochen-Bereich:
$108.94
$112.87
52-Wochen-Spanne:
$81.22
$118.30
Revvity Inc Stock (RVTY) Company Profile
Firmenname
Revvity Inc
Sektor
Branche
Telefon
781-663-6900
Adresse
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
110.15 | 12.46B | 2.90B | 239.11M | 492.62M | 2.1097 |
TMO
Thermo Fisher Scientific Inc
|
532.48 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.83 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.44 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
271.39 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
131.46 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-12-09 | Eingeleitet | Goldman | Neutral |
| 2025-10-16 | Eingeleitet | Guggenheim | Neutral |
| 2025-05-01 | Hochstufung | UBS | Neutral → Buy |
| 2025-01-10 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-08 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-23 | Fortgesetzt | Goldman | Buy |
Alle ansehen
Revvity Inc Aktie (RVTY) Neueste Nachrichten
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
Revvity stock trades steadily as recent earnings highlight growth and margin pressure - ad-hoc-news.de
Revvity Inc. stock outperforms competitors on strong trading day - MSN
TD Cowen Adjusts Price Target on Revvity to $130 From $120, Maintains Buy Rating - marketscreener.com
REVVITY INC : TD COWEN RAISES TARGET PRICE TO $130 FROM $120 - Moomoo
Revvity (RVTY) Investor Day 2024 Summary - Quartr
Revvity (RVTY) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Revvity (RVTY) Citi Annual Global Healthcare Conference 2025 Summary - Quartr
PKI4882935 Bond Risk Profile - TradingView
A184AM Bond Risk Profile - TradingView
A184AM Bond Coupon Profile — Rate & Payments - TradingView
PKI5255603 Bond Profile — Key Metrics - TradingView
S&P Global upgrades Revvity outlook on leverage improvement By Investing.com - Investing.com India
S&P Global upgrades Revvity outlook on leverage improvement - Investing.com
Revvity Inc. stock underperforms Monday when compared to competitors - MarketWatch
Revvity: Overvalued On Sentiment (NYSE:RVTY) - Seeking Alpha
Baird Adjusts Price Target on Revvity to $128 From $117, Maintains Outperform Rating - marketscreener.com
Revvity, Inc. Stock 12‑Month Price Target Raised to $116.07, Implies 3% Upside - TradingView
ETFs Investing in Revvity, Inc. Stocks - TradingView
RVTY Stock Price and Chart — NYSE:RVTY - TradingView
Revvity expands Signals AI with Anthropic Claude integration - MSN
Should Revvity’s (RVTY) Claude Integration Reframe How Investors View Its Data and AI Strategy? - Yahoo Finance
Revvity Inc (RVTY) Stock Up 3.3% and Still Undervalued -- GF Sco - GuruFocus
Precision Trading with Revvity Inc. (RVTY) Risk Zones - Stock Traders Daily
Revvity (RVTY) Joins Anthropic Directory To Bring Claude Into Signals Research Workflows - Yahoo Finance
Revvity Inc. focuses on life sciences tools as investors watch fundamentals - Ad-hoc-news.de
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Revvity to announce Q2 2026 results on August 4 - scanx.trade
Press Release: Revvity to Hold Earnings Call on Tuesday, August 4, 2026 - Moomoo
Revvity to Hold Earnings Call on Tuesday, August 4, 2026 - Business Wire
Revvity Inc. outlines its life sciences focus as a diversified tools provider - Ad-hoc-news.de
Revvity Inc. outlines its life sciences focus as investors track its Nasdaq listing - ad-hoc-news.de
Evercore Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $125 - Moomoo
RVTY Maintained by Evercore ISI Group -- Price Target Raised to $125 - GuruFocus
Evercore ISI Adjusts Price Target on Revvity to $125 From $110 - Moomoo
Revvity stock leans on its diagnostics and discovery base. - ad-hoc-news.de
Revvity Signals Radiometric Detection SystemA classic workhorse for high-throughput labs - AD HOC NEWS
Revvity Inc. strategy supports long-term growth amid evolving life sciences demand - ad-hoc-news.de
Revvity Inc. highlights its life sciences role as investors weigh long term growth - AD HOC NEWS
Revvity Inc. outlines its diagnostics and life-science focus for investors - AD HOC NEWS
What You Need to Know Ahead of Revvity’s Earnings Release - Barchart.com
Revvity Inc. focuses on life sciences tools as investors weigh long-term growth prospects - AD HOC NEWS
Revvity Expands Signals AI With Anthropic Claude Integration - Yahoo Finance
3 Reasons to Avoid RVTY and 1 Stock to Buy Instead - The Globe and Mail
Revvity (RVTY) Enhances R&D Access through Partnership with Anth - GuruFocus
Revvity Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Revvity, Inc. Expands Signals AI Ecosystem Through Anthropic Claude Integration - marketscreener.com
Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration - 01net
Revvity adds Signals connector to Anthropic’s Claude platform By Investing.com - Investing.com South Africa
Revvity adds Signals connector to Anthropic’s Claude platform - Investing.com
The EnLite Neonatal TREC kit from Revvity Inc.newborn screening focuses on severe immune defects - AD HOC NEWS
Finanzdaten der Revvity Inc-Aktie (RVTY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):